Northwest Biotherapeutics (NWBO) Stock Price, News & Analysis

Company Overview

Northwest Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.

The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial. In addition, Northwest Biotherapeutics is evaluating DCVax®-Direct, a novel formulation intended for direct injection into solid tumors, in Phase I/II studies. The company maintains an active pipeline exploring applications of its dendritic cell platform in other oncology indications.

Headquartered in Bethesda, Maryland, Northwest Biotherapeutics collaborates with research institutions and clinical centers across North America and Europe. These partnerships support ongoing trials, manufacturing scale-up, and regulatory interactions. The company’s leadership team comprises industry veterans with expertise in immunology, clinical development, and regulatory affairs, all working to advance personalized immunotherapy as a new standard of care in oncology.

Key Stats

• Today's Range: $0.16 to $0.17
• 50-Day Range: $0.15 to $0.23
• 52-Week Range: $0.14 to $0.37
• Volume: 1.26 million shs
• Average Volume: 3.33 million shs
• Market Capitalization: $276.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Northwest Biotherapeutics Stock Analysis - MarketRank™

Northwest Biotherapeutics scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Northwest Biotherapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Northwest Biotherapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Northwest Biotherapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.25% of the float of Northwest Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Northwest Biotherapeutics has a short interest ratio ("days to cover") of 9.24.

Change versus previous month

Short interest in Northwest Biotherapeutics has recently increased by 2.14%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Northwest Biotherapeutics does not currently pay a dividend.

Dividend Growth

Northwest Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: N/A

News Sentiment

Northwest Biotherapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Healthcare companies.

MarketBeat Follows

3 people have added Northwest Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Northwest Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.40% of the stock of Northwest Biotherapeutics is held by insiders.

Percentage Held by Institutions

0.04% of the stock of Northwest Biotherapeutics is held by institutions.

Company Calendar

• Last Earnings: 11/14/2025
• Today: 8/01/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:NWBO
• Previous Symbol: NASDAQ:NWBO
• CIK: 1072379
• Web: www.nwbio.com
• Phone: (240) 497-9024
• Fax: 240-627-4121
• Employees: 20
• Year Founded: 1998

Profitability

• EPS (Trailing Twelve Months): ($18.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$60.16 million
• Net Margins: -2,931.73%
• Pretax Margin: -2,967.60%
• Return on Equity: N/A
• Return on Assets: -79.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.07
• Quick Ratio: 0.07

Sales & Book Value

• Annual Sales: $1.38 million
• Price / Sales: 200.61
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.04) per share
• Price / Book: -4.10

Miscellaneous

• Outstanding Shares: 1,688,070,000
• Free Float: 1,647,560,000
• Market Cap: $276.84 million
• Optionable: Not Optionable
• Beta: -0.63